Vaishali Pharma (VAISHALI) Q4 19/20 earnings summary

Executive summary

• FY20 revenue was ₹62.26 crore vs ₹77.07 crore in FY19; net profit fell to ₹3.28 lakh from ₹71.36 lakh, with large bad-debt and receivable write-offs weighing on results.

• Operations span pharmaceutical products, APIs, formulations, surgical goods, herbal and nutraceutical products, and veterinary supplements across domestic and export markets.

• The outlook emphasized repeat customer orders, cost reduction and margin improvement, while COVID-19 created near-term operating and demand uncertainty.

Financial highlights

• Revenue from operations was ₹60.09 crore vs ₹75.09 crore in FY19; other income was ₹2.17 crore vs ₹1.98 crore, taking total income to ₹62.26 crore vs ₹77.07 crore.

• Expenses totaled ₹62.18 crore vs ₹75.94 crore; PBT was ₹7.91 lakh vs ₹1.13 crore, and net profit was ₹3.28 lakh vs ₹71.36 lakh.

• Other expenses included ₹3.47 crore of bad debts written off; cash-flow adjustments also included ₹4.17 crore for bad debts and other receivables written off.

• EPS was ₹0.03 vs ₹0.68; the prior-period EPS was adjusted for the bonus issue, with 1.0546 crore weighted-average shares in both periods.

• Export-goods foreign exchange inflow was ₹13.05 crore vs ₹14.01 crore in FY19.

Outlook and guidance

• Repeat orders and major customer orders supported activity; cost-reduction initiatives aimed to improve margins and overall profitability in coming years.

• Management cited customer and partner relationships, diversified business, execution capability and global reach as supports for navigating the pandemic and pursuing market-share opportunities.

• COVID-19 risks included lockdown-related manufacturing and R&D disruption, logistics and material constraints, weaker customer demand, and increased cyber risk under remote work.